MedTrace Logo

CD38 Targeted -PET/ CT for Multiple Myeloma

NCT07782944 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-08-24

No results posted yet for this study

Summary

The objective of the study is to construct a noninvasive approach CD38 targeted PET/CT to detect tumor lesions in patients with Multiple Myeloma and to compare with FDG PET/CT.

Conditions

  • Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma

Interventions

DIAGNOSTIC_TEST

standard-of-care imaging (FDG PET/CT), CD38 PET/CT

Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceutical (FDG) and CD38, and undergoes PET/CT imaging within the specified time.

Sponsors & Collaborators

  • Guilin Medical University, China

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-07
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07782944 on ClinicalTrials.gov